Quotas Are Constraints, Not Goals — Building Materials That Resist the Pull of Numbers

"Have you been watching this month's numbers?" — a single line from a manager can quietly reshape how a materials author works. The approved data hasn't changed, yet the emphasis shifts. The safety section gets shorter. An unfavorable trial result migrates to an appendix. Targets don't need to disappear; they shouldn't. But the moment a target becomes a goal, the line we're supposed to hold as materials authors starts moving — without anyone announcing it. This piece is about noticing that movement before it goes too far.

So What / So Why — Why This Conviction Matters

Materials authors can look like they're farther from the numbers than MRs are. In practice, the finished materials get evaluated by prescription results. When marketing KPIs list prescription share, adoption rates, and new prescribers acquired after symposia, materials get measured by outcomes too. The requests that follow — "this slide isn't landing," "make it more memorable" — arrive in the language of numbers. As long as those requests stay within the bounds of scientific evidence, there's no problem. The problem starts when the requests exceed those bounds and the materials author processes the excess as an "adjustment."

Why "adjustment"? Because motivated reasoning kicks in. The chain runs something like: this drug is genuinely good — so more patients should receive it — so growing prescriptions is the right outcome — so materials that support that outcome are justified. Each link looks harmless. Together they erase the original question, which is simple: does this statement accurately reflect the approved scientific evidence? That's the only question.

Real incidents make this concrete. Most of the deviations recorded in the monitoring program reports started with the materials themselves. Symposium slides were structured to imply off-label indications. Slides labeled "general information" contained steered pathways toward a specific product. Instructions for working around long-term prescription restrictions were passed verbally; the materials stayed within "acceptable" bounds on paper. When numbers become the goal, this kind of splitting happens: the problematic content moves outside the materials, while the materials themselves look compliant. That isn't fraud in any obvious sense. It is an absence of integrity.

The Conviction — What I Want to Stand For

I want to read target numbers as constraints. A constraint defines the outer boundary of the space I can work in. A goal is what I choose to achieve within that space. Conflating the two turns growing numbers into the purpose, and scientific evidence into a tool for that purpose. Once evidence becomes a tool, only the convenient parts get called evidence.

What I want to manage in materials is evidentiary completeness. If I present efficacy data, I present safety data with equal weight. If I highlight a subgroup analysis, I make it visible that the result comes from a subgroup. I don't include suggestions pointing toward unapproved indications, in any form. This isn't defensiveness or excessive caution. It's a sense of responsibility toward the work itself: delivering an accurate picture of this drug to the physicians who will prescribe it.

Holding to this is genuinely difficult. Near the end of a quarter someone says "push a little further." A competitor's materials look bolder. Familiarity with the product you manage builds a sense that "this much is probably fine." I can't honestly say I've never felt that pull. That's why I'm writing this as a conviction — something to come back to when the pull is there, to check where I'm trying to stand.

Daily Practice — Concrete Actions and Checks

A conviction stated once doesn't function on its own. Embedding it in daily judgment requires specific questions.

• Put into words why you chose this data. Selection happens easily without awareness. Did you choose this efficacy graph because it's scientifically most representative, or because it looks best? Articulating the reason makes the reason visible.
• Maintain a conscious list of what you left out. What's excluded matters as much as what's included. Safety information. Subgroup results that show limits on efficacy. Direct comparison data against competitors. Ask yourself whether each exclusion is because the data is scientifically inappropriate — or because it creates a bad impression.
• Read the materials as a monitoring program monitor would. The Ministry of Health, Labour and Welfare's monitoring program uses monitors on the healthcare provider side who record and report the specific content of promotional communications. Reading your own materials through that lens sometimes shakes a self-assessment of "no issues here." If it shakes, revision is needed.
• When a numeric demand comes in, ask what the evidence is. When a request arrives to "put efficacy front and center," check whether there is additional approved evidence that supports doing so. If there isn't, state quietly that the request is commercial rather than scientific.
• Look at the materials on a three-year horizon. Quarterly numbers disappear in three months; the influence of materials doesn't. Information that settles into clinical practice can persist as prescribing habit even after the materials are updated.

When the Line Gets Tested — Under Pressure

What specific situations test the line?

Two weeks before the end of a quarter, the product manager reaches out. "The current symposium slides aren't moving prescribing intent. The competition is going further. We need a revision in time for the next facility visits." A revision request is a legitimate work task. The content is where it matters. "Going further" means something entirely different depending on whether it means more accurate information, more favorable data emphasized, or an off-label suggestion — and the response has to match the actual meaning.

The first psychological move in that moment is local rationalization. "Competitors are doing it." "We're just preparing for when physicians ask." "It's framed as general information." Each judgment gets processed as a small exception. Stacked, they amount to a systematic deviation. The fork is here: whether you can form the question "what is the basis for this change?"

Another moment where the line gets tested is pre-screening speaker slides for symposia. When reviewing a KOL's slides in advance and finding off-label usage embedded in them — the speaker's authority, a long-standing relationship, deadline pressure — the feeling that it's hard to raise the issue is real. But if the issue isn't raised and the slides are distributed, the company has in effect co-endorsed the content. The symposium cases recorded in the Reiwa 7 (2025) report followed exactly this path.

The psychology of how people move under pressure is examined in depth in Series 2, "The Gravity of Numbers — The Psychology of Quotas and Incentives." That piece traces how motivated reasoning, local rationalization, and externalization of responsibility move people with genuine conscience — grounded in real cases.

Where to Stand — When Things Feel Like They're Breaking

When the pull of numbers gets strong, there is a place to come back to: the four principles in the Guidelines on Sales Information Activities for Prescription Drugs. Base everything on scientific and objective evidence. Provide information on both efficacy and safety. Compete fairly. Be transparent about conflicts of interest. These four points remind you what materials are actually for. Not for prescription counts. To deliver evidence so physicians can make accurate judgments for their patients.

"Both efficacy and safety" carries particular weight. Materials that highlight only efficacy — however precisely constructed — are one-sided as information. Physicians make prescribing decisions from both sides. Handing over one side and calling it accurate information doesn't hold.

When things feel close to breaking, I go back and read cases from Series 1. Most of what's recorded in "Presenting Unapproved Indications and Dosages" sits at the end of a chain of decisions where numbers became the goal. The MR for a dyslipidemia drug who told physicians they could use the drug as monotherapy without insurance audit concerns by pairing it with a generic — that didn't come from bad intent. It came from the certainty that "this drug needs to reach patients." That certainty overrode the co-administration conditions in the package insert and dismantled the post-marketing safety surveillance framework. Materials authors can carry the same certainty. Certainty is dangerous precisely because it provides a feeling of doing the right thing.

Numbers are a measuring tool. When you forget what they're measuring, the tool becomes the goal. At the far end of that, there are patients. Those patients don't appear in the quarterly report.